Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Leah Friedman is active.

Publication


Featured researches published by Leah Friedman.


Nature Medicine | 2007

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam L. Boxer; Kaj Blennow; Leah Friedman; Douglas Galasko; Marek Jutel; Anna Karydas; Jeffrey Kaye; Jerzy Leszek; Bruce L. Miller; Lennart Minthon; Joseph F. Quinn; Gil D. Rabinovici; William H. Robinson; Marwan N. Sabbagh; Yuen T. So; D Larry Sparks; Massimo Tabaton; Jared R. Tinklenberg; Jerome A. Yesavage; Robert Tibshirani; Tony Wyss-Coray

A molecular test for Alzheimers disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimers and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimers disease 2–6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimers disease.


Journal of the American Geriatrics Society | 1994

Estrogen Replacement Therapy and Memory in Older Women

David A. Robinson; Leah Friedman; Robert Marcus; Jared R. Tinklenberg; Jerome A. Yesavage

OBJECTIVE: To study the relationship between estrogen hormone replacement therapy and recall of proper names and words in cognitively intact older women.


International Psychogeriatrics | 1991

Proposed Factor Structure of the Geriatric Depression Scale

Javaid I. Sheikh; Jerome A. Yesavage; John O. Brooks; Leah Friedman; Peter Gratzinger; Robert D. Hill; Anastasia Zadeik; Thomas H. Crook

The Geriatric Depression Scale (GDS) is commonly used to measure depression in the elderly. However, there have been no reports of the underlying structure of the GDS. To this end, the GDS was administered to 326 community-dwelling elderly subjects, and the data were subjected to a factor analysis. A five-factor solution was selected and, after a varimax rotation, the factors that emerged could be described as: (1) sad mood, (2) lack of energy, (3) positive mood, (4) agitation, and (5) social withdrawal. This solution accounted for 42.9% of the variance. Knowledge of the factor structure should aid both clinicians and researchers in the interpretation of responses on the GDS.


Neurology | 2002

Donepezil and flight simulator performance: Effects on retention of complex skills

Jerome A. Yesavage; Martin S. Mumenthaler; Joy L. Taylor; Leah Friedman; Ruth O'Hara; Javaid I. Sheikh; Jared R. Tinklenberg; P. J. Whitehouse

Abstract—We report a randomized, double-blind, parallel group, placebo-controlled study to test the effects of the acetylcholinesterase inhibitor, donepezil (5 mg/d for 30 days), on aircraft pilot performance in 18 licensed pilots with mean age of 52 years. After 30 days of treatment, the donepezil group showed greater ability to retain the capacity to perform a set of complex simulator tasks than the placebo group, p < 0.05. Donepezil appears to have beneficial effects on retention of training on complex aviation tasks in nondemented older adults.


Journal of Geriatric Psychiatry and Neurology | 2000

An Actigraphic Comparison of Sleep Restriction and Sleep Hygiene Treatments for Insomnia in Older Adults

Leah Friedman; Kathleen L. Benson; Art Noda; Vincent P. Zarcone; Deryl A. Wicks; Kerry O'Connell; John O. Brooks; Donald L. Bliwise; Jerome A. Yesavage

We compared the efficacy of sleep restriction therapy combined with sleep hygiene, nap modification of sleep restriction therapy combined with sleep hygiene, and sleep hygiene alone as treatments for insomnia in 39 community-dwelling men and women 55 years and older. We used the wrist actigraph as an objective outcome measure for all subjects at baseline, end of treatment, and 3-month follow-up; polysomnography (PSG) was conducted in a subgroup of subjects. Although subjects appeared to follow restriction instructions through follow-up, we found few between-group differences in treatment efficacy. Lack of treatment effect might be explained by the efficacy of HYG as a treatment in itself and the relatively low symptom level in these healthy older poor sleepers. At baseline, actigraphic results were found to correlate more highly than sleep log data with PSG in our sample. Actigraphic total sleep time, in particular, was highly correlated with PSG. (J Geriatr Psychiatry Neurol 2000; 13:17-27).


Journal of the American Geriatrics Society | 1998

The APOE ∍4 allele Is Associated with Decline on Delayed Recall Performance in Community-Dwelling Older Adults

Ruth O'Hara; Jerome A. Yesavage; Helena C. Kraemer; Maritess Mauricio; Leah Friedman; Greer M. Murphy

OBJECTIVE: This study investigated whether the Apolipoprotein (APOE) ∍4 allele was associated with cognitive decline in community‐dwelling older adults.


Journal of Geriatric Psychiatry and Neurology | 2003

Development of diagnostic criteria for defining sleep disturbance in Alzheimer's disease.

Jerome A. Yesavage; Leah Friedman; Sonia Ancoli-Israel; Donald L. Bliwise; Clifford M. Singer; Michael V. Vitiello; Andrew A. Monjan; Barry Lebowitz

This article proposes new standards for identifying, defining, and naming sleep/wake cycle disturbances associated with Alzheimers disease (AD) to aid in more effective research, including the development and testing of potential treatments. Many AD patients develop sleep/wake cycle disturbances associated with distress, depression, and sleep disturbances in the caregiver, as well as early nursing home placement for the patient. The Food and Drug Administration Psychopharmacological Drugs Advisory Committee has emphasized the need for a comprehensive diagnostic system. A key point made by the committee was that behavioral problems associated with dementia (including sleep and chronobiological disturbances) are scientifically and clinically valid targets of pharmacologic treatment. However, current diagnostic criteria preclude development of FDA-acceptable studies of pharmacological interventions because they do not include the required specific indications for treatment. This article attempts to develop better-defined provisional criteria with the goal of promoting epidemiological, physiological, and, especially, pharmacological research on sleep/wake disturbances. (J Geriatr Psychiatry Neurol 2003; 16:131-139)


Journal of Psychiatric Research | 2002

Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment

Jerome A. Yesavage; Ruth O’Hara; Helena C. Kraemer; Art Noda; Joy L. Taylor; Steve Ferris; Marie-Christine Gély-Nargeot; Allyson Rosen; Leah Friedman; Javaid I. Sheikh; Christian Derouesné

A number of systems have been proposed for classifying older adults who suffer from cognitive impairment or decline but do not yet meet criteria for Alzheimers disease (AD). The classification, Mild Cognitive Impairment (MCI), has attracted much attention. It uses relatively specific diagnostic criteria and individuals who meet these criteria appear to be at substantial risk for the development of AD. However, little data is available to define the prevalence of MCI in any age group. We propose a simple mathematical model for the progression of patients from Non-Affected (NA) to MCI to AD. This first-order Markov model defines the likely prevalence of MCI at specific ages. Primary assumptions of the model include an AD prevalence of 1% at age 60 increasing to 25% at age 85 and a conversion rate from MCI to AD of 10% constant across all ages considered. We used the best available information for our model and found (1) that the MCI prevalence increased from 1% at age 60 to 42% at age 85 and (2) that the conversion rate from NA to MCI increased from 1% per year at age 60 to 11% at age 85. In conclusion, this model allows estimation of prevalence of MCI and conversion from NA to MCI based upon known prevalences of AD, conversion rates of MCI to AD, and death rates. Due to its substantial prevalence, MCI may be an important target for screening and possible intervention.


Psychology and Aging | 1990

Learning mnemonics: roles of aging and subtle cognitive impairment.

Jerome A. Yesavage; Javaid I. Sheikh; Leah Friedman; Elizabeth Decker Tanke

Previously validated methods of memory training were used in conjunction with the Folstein Mini-Mental State Examination (MMSE) to explore the relationship between complexity of learned mnemonic, aging, and subtle cognitive impairment. Subjects were 218 community-dwelling elderly. Treatment included imagery mnemonics for remembering names and faces and lists. There was a significant interaction among age, type of learning task (face-name vs. list), and improvement when controlling for MMSE score. There was also a significant interaction among MMSE score, type of learning task, and improvement when controlling for age. Scores on the more complex list-learning mnemonic were more affected by age and MMSE scores than were scores on the face-name mnemonic. Implications of the findings for cognitive training of the old old and the impaired are discussed.


Journal of Rehabilitation Research and Development | 2009

Insomnia in the context of traumatic brain injury

Jamie M. Zeitzer; Leah Friedman; Ruth O'Hara

Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality in the United States. One of the most common comorbidities of TBI is the disruption of normal sleep. While often viewed as a nuisance symptom, sleep disruption can delay TBI recovery and negatively affect many of the psychological (e.g., anxiety, depression) and neuromuscular (e.g., pain) sequelae of TBI, decreasing quality of life. Treatment of sleep disruption in the context of TBI is complicated by issues of an altered neuronal milieu, polypharmacy, and the complex relationship between the various comorbidities often found in patients with TBI. Given the growing number of veterans returning from combat with TBI and the elevated risk of comorbid disrupted sleep, both caused by and independent of TBI, a comprehensive review of sleep disruption and its treatment is of great relevance to the Department of Veterans Affairs.

Collaboration


Dive into the Leah Friedman's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge